Natalie F. Uy

Dr. Natalie F. Uy

University of Washington, Seattle, Washington, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Natalie F. UyNatalie F. Uy
Natalie F. Uy
CMCristina M. Merkhofer
Cristina M. Merkhofer
CBChristina S. Baik
Christina S. Baik
Human epidermal growth factor receptor 2 (HER2), a member of the ERBB family of tyrosine kinase receptors, has emerged as a therapeutic target of interest for non-small cell lung cancer (NSCLC) in recent years. Activating HER2 alterations in NSCLC include gene mutations, gene amplifications, and protein overexpression. In particular, the HER2 exon 20 mutation is now a well clinically validated biomarker. Currently, there are limited targeted therapies approved for NSCLC patients with HER2 alterations. This remains an unmet clinical need, as HER2 alterations are present in 7–27% of de novo NSCLC and may serve as a resistance mechanism in up to 10% of EGFR mutated NSCLC. There has been an influx of research on antibody–drug conjugates (ADCs), monoclonal antibodies, and tyrosine kinase inhibitors (TKIs) with mixed results. The most promising therapies are ADCs (trastuzumab-deruxtecan) and novel TKIs targeting exon 20 mutations (poziotinib, mobocertinib and pyrotinib); both have resulted in meaningful anti-tumor efficacy in HER2 mutated NSCLC. Future studies on HER2 targeted therapy will need to define the specific HER2 alteration to better select patients who will benefit, particularly for HER2 amplification and overexpression. Given the variety of HER2 targeted drugs, sequencing of these agents and optimizing combination therapies will depend on more mature efficacy data from clinical trials and toxicity profiles. This review highlights the challenges of diagnosing HER2 alterations, summarizes recent progress in novel HER2-targeted agents, and projects next steps in advancing treatment for the thousands of patients with HER2 altered NSCLC.

15 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
SWSarah Waliany
Sarah Waliany
ACAlissa J. Cooper
Alissa J. Cooper
Stephen LiuStephen Liu
Stephen Liu
OGOliver Gautschi
Oliver Gautschi
JRJulia K. Rotow
Julia K. Rotow
JLJessica J. Lin
Jessica J. Lin
Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.

16 March 2026
Verified
Other
Open access
SWSarah Waliany
Sarah Waliany
ACAlissa J. Cooper
Alissa J. Cooper
Stephen LiuStephen Liu
Stephen Liu
OGOliver Gautschi
Oliver Gautschi
JRJulia K. Rotow
Julia K. Rotow
JLJessica J. Lin
Jessica J. Lin
Clinical and Molecular Characteristics of Cases of RET Gain Identified by Next-Generation Sequencing after Selective RET Inhibitors

16 March 2026
Verified
Other
Open access
SWSarah Waliany
Sarah Waliany
ACAlissa J. Cooper
Alissa J. Cooper
Stephen LiuStephen Liu
Stephen Liu
OGOliver Gautschi
Oliver Gautschi
JRJulia K. Rotow
Julia K. Rotow
JLJessica J. Lin
Jessica J. Lin
Pre- and post-SRI next-generation sequencing results provided

16 March 2026
Verified
Other
Open access
SWSarah Waliany
Sarah Waliany
ACAlissa J. Cooper
Alissa J. Cooper
Stephen LiuStephen Liu
Stephen Liu
OGOliver Gautschi
Oliver Gautschi
JRJulia K. Rotow
Julia K. Rotow
JLJessica J. Lin
Jessica J. Lin
Clinical and Molecular Characteristics of Cases of Acquired MET Amplification Identified by Next-Generation Sequencing after Selective RET Inhibitors

16 March 2026
Verified
Other
Open access
SWSarah Waliany
Sarah Waliany
ACAlissa J. Cooper
Alissa J. Cooper
Stephen LiuStephen Liu
Stephen Liu
OGOliver Gautschi
Oliver Gautschi
JRJulia K. Rotow
Julia K. Rotow
JLJessica J. Lin
Jessica J. Lin
Acquired genomic alterations identified by post-progression biopsies after selective RET inhibitors